Jeremy Sugarman, MD, MPH, MA

Deputy Director for Medicine; Harvey M. Meyerhoff Professor of Bioethics and Medicine

Contact

1809 Ashland Ave.
Room 203
Baltimore, MD 21205
410-614-5634
[email protected]
People
  • Deputy Director for Medicine
    Johns Hopkins Berman Institute of Bioethics
  • Harvey M. Meyerhoff Professor of Bioethics and Medicine
    Johns Hopkins Berman Institute of Bioethics
    Johns Hopkins School of Medicine
  • Professor of Health Policy and Management
    Johns Hopkins Bloomberg of Public Health

Jeremy Sugarman, MD, MPH, MA is the Harvey M. Meyerhoff Professor of Bioethics and Medicine, professor of medicine, professor of Health Policy and Management, and deputy director for medicine of the Berman Institute of Bioethics at the Johns Hopkins University. He is an internationally recognized leader in bioethics with particular expertise in applying empirical methods and evidence-based standards for evaluating and analyzing bioethical issues. His contributions to bioethics and policy include his work on the ethics of informed consent, umbilical cord blood banking, stem cell research, international HIV prevention research, global health and research oversight.

Dr. Sugarman is the author of over 400 articles, reviews and book chapters.  He has also edited or co-edited four books (Beyond Consent: Seeking Justice in Research; Ethics of Research with Human Subjects: Selected Policies and Resources; Ethics in Primary Care; and Methods in Medical Ethics).  Dr. Sugarman is on the editorial boards of several academic journals.

Dr. Sugarman consults and speaks internationally on a range of issues related to bioethics. He was senior policy and research analyst for the White House Advisory Committee on Human Radiation Experiments, consultant to the National Bioethics Advisory Commission, and Senior Advisor to the Presidential Commission for the Study of Bioethical Issues. He also served on the Maryland Stem Cell Research Commission.

Read More

He was the founding director of the Trent Center for Bioethics, Humanities and History of Medicine at Duke University where he was also a professor of medicine and philosophy. He was appointed as an Academic Icon at the University of Malaya and is a faculty affiliate of the Kennedy Institute of Ethics at Georgetown University.

Dr. Sugarman was the longstanding chair of the Ethics Working Group of the HIV Prevention Trials Network. He is currently a member of the Scientific and Research Advisory Board for the Canadian Blood Service and the Ethics and Public Policy Committees of the International Society for Stem Cell Research. He co-leads the Ethics and Regulatory Core of the NIH Health Care Systems Research Collaboratory and is co-chair of the Johns Hopkins’ Institutional Stem Cell Research Oversight Committee.

Dr. Sugarman has been elected as a member of the American Society of Clinical Investigation, Association of American Physicians, and the National Academy of Medicine (formerly the Institute of Medicine). He is a fellow of the American Association for the Advancement of Science, the American College of Physicians and the Hastings Center. He also received a Doctor of Science, honoris causa, from New York Medical College.

Research Interests

  • Informed consent
  • Stem cell research
  • International HIV prevention research
  • HIV cure research
  • Global health
  • Emerging technologies
  • Research oversight
  • Methods in bioethics
  • Pragmatic clinical trials
  • Clinical trial design
  • Umbilical cord blood banking

Education

  • B.S., Duke University
  • M.D., Duke University School of Medicine
  • M.P.H., Johns Hopkins Bloomberg School of Public Health
  • M.A., Applied Ethics, Georgetown University

Activities

  • Co-Chair, Institutional Stem Cell Research Oversight Committee, Johns Hopkins University

Recent Publications

  1. Bollinger J, May E, Mathews D, Donowitz M, Sugarman J. Patients’ perspectives on the derivation and use of organoids. Stem Cell Reports2021: S2213-6711(21)00329-5. doi: 10.1016/j.stemcr.2021.07.004. PMID: 34329595.
  2. Sugarman J, Donnell DJ, Hanscom B, McCauley M, Grinsztejn B, Landovitz RJ. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. Lancet HIV 2021; S2352-3018(21)00153-3. doi: 10.1016/S2352-3018(21)00153-3. PMID: 34454678.
  3. Morain SR, Kraft SA, Wilfond BS, McGuire A, Dickert NW, Garland A, Sugarman J. Toward meeting the obligation of respect for persons in pragmatic clinical trials. Hastings Cent Rep 2022; 52:9-17. doi: 10.1002/hast.1391. PMID: 35763201.
  4. Modlin CE, DeCamp M, Barry M, Rockney D, Sugarman J. An online ethics curriculum for short-term global health experiences: evaluating a decade of use. Ann Glob Health. 2022; 88: 74. doi: 10.5334/aogh.3716. PMID: 36072830.
  5. Morain SR, Bollinger J, Weinfurt K, Sugarman J. Ethics challenges in sharing data from pragmatic clinical trials. Clin Trials 2022;19: 681-689. doi: 10.1177/17407745221110881. PMID: 36071689.
  6. Brems JH, Ferryman K, McCormack MC, Sugarman J. Ethical considerations regarding the use of race in pulmonary function testing. Chest2022;162: 878-881. doi: 10.1016/j.chest.2022.05.006. PMID: 36210104.
  7. Garland A, Morain S, Sugarman J. Do clinicians have a duty to participate in pragmatic clinical trials? Am J Bioeth. 2023; 23:22-32. doi: 10.1080/15265161.2022.2146784. PMID: 36449269.
  8. Bollinger JM, Geller G, May E, Brewer J, Henry LM, Sugarman J. Challenges in obtaining the informed perspectives of stakeholders regarding HIV molecular epidemiology. J Acquir Immune Defic Syndr 2023 Feb 21. doi: 10.1097/QAI.0000000000003179. Epub ahead of print. PMID: 36805407.
  9. Vayena E, Blasimme A, Sugarman J. Decentralised clinical trials: ethical opportunities and challenges. Lancet Digit Health 2023 Apr 25: S2589-7500(23)00052-3. doi: 10.1016/S2589-7500(23)00052-3. Epub ahead of print. PMID: 37105800.
  10. Tackett S, Jenn Ng C, Sugarman J, Daniel EGS, Gopalan N, Tivyashinee, Kamarulzaman A, Ali J. A competency framework for health research ethics educational programs: results from a stakeholder-driven mixed-method process. Ethics Hum Res 2023; 45:29-39. doi: 10.1002/eahr.500166. PMID: 37167475.
  11. Sugarman J, Wenner DM, Rid A, Henry LM, Luna F, Klitzman R, MacQueen KM, Rennie S, Singh JA, Gostin LO. Ethical research when abortion access is legally restricted. Science 2023;380(6651):1224-1226. doi: 10.1126/science.adh3104. PMID: 37347876.
  12. Blasimme A, Sugarman J. Human stem cell-derived embryo models: Toward ethically appropriate regulations and policies. Cell Stem Cell2023 Jun 30:S1934-5909(23)00218-7. doi: 10.1016/j.stem.2023.06.007. Epub ahead of print. PMID: 37402374.
  13. Sugarman J, Taylor HA, Bachmann LH, Barbee LA, Cahill S, Celum C, Luetkemeyer AF, Mayer KH, Mena L, Mermin J, Upshur R, Aral S. Ethical considerations in implementing doxycycline post-exposure prophylaxis for the prevention of bacterial sexually transmitted infections. Sex Transm Dis 2023 Dec 7. doi: 10.1097/OLQ.0000000000001907. Epub ahead of print. PMID: 38079243.

Related Projects

NIH Health Care System Research Collaboratory Regulatory/Ethics Core

Navigating regulatory and ethical complexities associated with pragmatic clinical trials in health care systems

PCORnet Ethics and Regulatory Task Force

Addressing the ethical and regulatory issues related to research that arise in PCORI’s work